

## A UNIQUE NATIONAL NETWORK TO PROMOTE VACCINE CLINICAL RESEARCH IN FRANCE

>30

## Clinical centres

Associated to a network of Biological Resource Centres (BRC)

Immunology research laboratories

Ongoing clinical studies

volonteers included on the CoV-IREIVAC plateform

**I-REIVAC** brings together various actors in a unique national task force to promote innovative clinical research on active and passive immunisation for the prevention of infectious diseases.

Vaccines & monoclonal antibodies

Healthy & specific populations

Phase 1 to 4 trials

Epidemiological & acceptability/ studies

## WHAT WE DO

Centre pre-selection

**Feasibility** studies

Study implementation

Recrutement follow up

**Point of** contact Team

Coordination

Communication

**Animation** 

**Valorization** 

 Produce reliable & high-quality data Save time setting up studies

SINCE 2007, I-REIVAC, AN F-CRIN LABELED NETWORK OF EXCELLENCE, GATHERS CLINICIANS AND RESEARCHERS FROM HOSPITALS ET UNIVERSITIES, WORKING ALONGSIDE THE INDUSTRY.

The network conducts phase 1 to 4 clinical trials and implements large-scale epidemiological monitoring studies.



## A NETWORK FOCUSSED ON VACCINOLOGY

- Network specialised in emerging infectious diseases
- Network of BRCs qualified in PBMC preparation
- Network of laboratories expert in the monitoring of vaccine immune responses



Clinical centres

Immunomonitoring labs

I-REIVAC coordination

- One-stop shop approach with the coordination team
- Nationwide network able to carry out several trials simultaneously
- A permanent structure that can ramp up in the event of an epidemic



- A national register of more that 56,000 volunteers
- Volunteers ready and motivated to take part in clinical trials
- Rapid access to targeted populations (healthy, immunodeficient, rare and/or chronic diseases, ...)
- Strengthens France's visibility and competitiveness in vaccine research.
- Develops a high-end, innovative and attractive scientific programs for academic and industrial partners.
- Promotes French vaccinology excellence by carrying out studies on an international scale, and early phase trials 1 & 2 and épidemiologycal studies in collaboration with the pharmaceutical industry, biotechnology companies, etc.
- Builds solid and effective European and international partnerships

Coordinated by the Pr. Odile Launay & the Pr. Eric Tartour







